Message from the Guest Editor

Dear Colleagues,

Genomic profiling technologies have experienced major improvements in recent years. Such advances have facilitated the discovery of potential tumor markers with improved sensitivities and specificities for the diagnosis, prognosis and treatment monitoring of cancer patients. From the discovery of novel biomarkers, there is still a large gap until they are translated into clinical applications. In the era of big data and precision medicine, novel gene interactions in various signaling pathways can be revealed with clinical significance. In line with this, the process of developmental mechanisms in tumorigenesis is generating new knowledge which will improve future cancer patients’ treatment strategies.

Prof. Benjamin Yat-Ming Yung
Guest Editor